Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

NCT07327411 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Advanced Refractory Solid Tumors

Interventions

RADIATION: Hypofractionated radiotherapy
DRUG: PD-L1 inhibitor
DRUG: GM-CSF
DRUG: anti-EGFR monoclonal antibody

Sponsor

Second Affiliated Hospital of Soochow University